Stay updated on ARGX-113 in Myasthenia Gravis: Safety Trial

Sign up to get notified when there's something new on the ARGX-113 in Myasthenia Gravis: Safety Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARGX-113 in Myasthenia Gravis: Safety Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of ARGX-113 in patients with Myasthenia Gravis who have generalized muscle weakness.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:00.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for patients, specifying both inclusion and exclusion criteria for the clinical trial. This change provides more comprehensive information about the requirements for patient participation in the study.
    Difference
    16%
    Check dated 2024-05-22T21:29:14.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T23:00:45.000Z thumbnail image

Stay in the know with updates to ARGX-113 in Myasthenia Gravis: Safety Trial

Enter your email address, and we'll notify you when there's something new on the ARGX-113 in Myasthenia Gravis: Safety Trial page.